Werewolf Therapeutics, Inc. (HOWL) Financials
Annual revenue, profitability and per-share results for Werewolf Therapeutics, Inc., as reported in SEC filings.
Revenue • FY2025
$0
Net income • FY2025
-$60.82M
▲ 13.7%YoY
Diluted EPS • FY2025
-$1.33
▲ 18.4%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$60.82M | — | -$1.33 | -$60.29M | — | — |
| FY2024 | $0 | -$70.52M | — | -$1.63 | -$56.44M | — | — |
| FY2023 | $0 | -$37.37M | — | -$1.05 | -$33.38M | — | — |
| FY2022 | $0 | -$53.81M | — | -$1.86 | -$44.21M | — | — |
Figures as reported in Werewolf Therapeutics, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a HOWL filing.
Get an email when HOWL files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.